Danaher Co. (NYSE:DHR) Shares Sold by Acorn Creek Capital LLC

Acorn Creek Capital LLC lessened its position in shares of Danaher Co. (NYSE:DHR) by 22.6% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,041 shares of the conglomerate’s stock after selling 595 shares during the period. Acorn Creek Capital LLC’s holdings in Danaher were worth $568,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of DHR. Benjamin Edwards Inc. raised its stake in shares of Danaher by 1.8% in the 2nd quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock valued at $538,000 after purchasing an additional 38 shares in the last quarter. Wedge Capital Management L L P NC raised its stake in shares of Danaher by 3.2% in the 3rd quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock valued at $342,000 after purchasing an additional 38 shares in the last quarter. Patrick M Sweeney & Associates Inc. raised its stake in shares of Danaher by 3.4% in the 2nd quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate’s stock valued at $307,000 after purchasing an additional 40 shares in the last quarter. Trust Co of Kansas raised its stake in shares of Danaher by 4.1% in the 2nd quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate’s stock valued at $255,000 after purchasing an additional 40 shares in the last quarter. Finally, Abacus Planning Group Inc. raised its stake in shares of Danaher by 0.7% in the 2nd quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate’s stock valued at $1,359,000 after purchasing an additional 40 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Activity

In other news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CFO Matthew Mcgrew sold 16,172 shares of the firm’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total value of $4,525,572.48. Following the transaction, the chief financial officer now directly owns 29,407 shares in the company, valued at approximately $8,229,254.88. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 39,659 shares of company stock worth $11,042,433. 11.10% of the stock is owned by corporate insiders.

Danaher Trading Up 0.4 %

Danaher stock opened at $272.68 on Wednesday. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $281.70. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The firm has a market capitalization of $201.97 billion, a price-to-earnings ratio of 46.22, a P/E/G ratio of 4.49 and a beta of 0.83. The company has a 50 day moving average price of $270.43 and a 200 day moving average price of $259.59.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. The company’s revenue was down 2.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.05 EPS. Research analysts forecast that Danaher Co. will post 7.59 EPS for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be issued a dividend of $0.27 per share. The ex-dividend date is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.40%. Danaher’s dividend payout ratio is currently 18.31%.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on DHR. TD Cowen increased their price objective on shares of Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a research note on Wednesday, July 24th. Leerink Partners increased their price objective on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Stifel Nicolaus increased their price objective on shares of Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a research note on Wednesday, July 24th. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $300.00 price target on shares of Danaher in a research note on Friday, September 6th. Seven analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $282.12.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.